RESUMEN
Inherited platelet function disorders are rare hemorrhagic diseases. The gold standard for their exploration is optical aggregometry; however, investigations by flow cytometry (FCM) are being increasingly used. In this review, the physiology of platelets is first recalled, setting the stage for the compartments of platelets that can be apprehended by specific and appropriate labeling. As this requires some pre-analytical precautions and specific analytical settings, a second part focuses on these characteristic aspects, based on literature and on the authors' experience in the field, for qualitative or quantitative explorations. Membrane labeling with antibodies to CD42a or CD41, respectively, useful to assess the genetic-related defects of Glanzmann thrombocytopenia and Bernard Soulier syndrome are then described. Platelet degranulation disorders are detailed in the next section, as they can be explored, upon platelet activation, by measuring the expression of surface P-Selectin (CD62P) or CD63. Mepacrin uptake and release after activation is another test allowing to explore the function of dense granules. Finally, the flip-flop anomaly related to Scott syndrome is depicted. Tables summarizing possible FCM assays, and characteristic histograms are provided as reference for flow laboratories interested in developing platelet exploration.
Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/sangre , Trastornos de las Plaquetas Sanguíneas/sangre , Citometría de Flujo , Inmunofenotipificación , Trastornos de la Coagulación Sanguínea Heredados/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea Heredados/genética , Trastornos de la Coagulación Sanguínea Heredados/inmunología , Trastornos de las Plaquetas Sanguíneas/tratamiento farmacológico , Trastornos de las Plaquetas Sanguíneas/inmunología , Trastornos de las Plaquetas Sanguíneas/patología , Plaquetas/efectos de los fármacos , Plaquetas/inmunología , Plaquetas/patología , Humanos , Activación Plaquetaria/genética , Activación Plaquetaria/inmunología , Quinacrina/uso terapéuticoAsunto(s)
Trastornos de la Coagulación Sanguínea Heredados/economía , Trastornos de la Coagulación Sanguínea Heredados/inmunología , Trastornos de la Coagulación Sanguínea Heredados/psicología , Trastornos de la Coagulación Sanguínea Heredados/terapia , Factores de Coagulación Sanguínea/antagonistas & inhibidores , Adolescente , Adulto , Anticuerpos/efectos adversos , Factores de Coagulación Sanguínea/inmunología , Transfusión Sanguínea , Niño , Preescolar , Costo de Enfermedad , Contaminación de Medicamentos/economía , Contaminación de Medicamentos/prevención & control , Factor IX/uso terapéutico , Factor VIII/uso terapéutico , Gastos en Salud , Humanos , Fragmentos Fc de Inmunoglobulinas/uso terapéutico , Infusiones Intravenosas/psicología , Aplicaciones Móviles , Calidad de Vida , Proteínas Recombinantes de Fusión/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Reino Unido , Juegos de VideoRESUMEN
Subcutaneous (SQ) vs. intramuscular (IM) vaccination may cause fewer injection site complications in children with bleeding disorders, but little is known about comparative immunogenicity. To compare immunogenicity of hepatitis B virus (HBV) vaccination administered SQ or IM to individuals <2 years old with bleeding disorders, we performed a retrospective analysis of HBV surface antibody titres among patients enrolled in the universal data collection database who had received three doses of HBV vaccine solely by one route (SQ or IM). Data reviewed were from an initial visit before 24 months of age, until time of hepatitis antibody titre testing. The SQ and IM study groups did not differ in demographics, haemophilia type or severity or bleeding history. The mean age at the time of HBV surface antibody (anti-HBs) testing was 56.9 ± 20.3 months. Eighty-five of 92 subjects (92.4%) who received vaccine SQ developed a positive antibody titre (>12 IU/L), compared to 101/114 (88.6%) who received IM (P = 0.30). There was no statistically significant difference in distribution of titre values. The average age of the subjects at time of testing was 53 ± 20 months in the SQ group vs. 60 ± 20 months in the IM group (P = 0.02). The average time between the last dose of vaccine and anti-HBs testing was 47.6 ± 18.5 months among SQ vaccinated subjects vs. 51.6 ± 20.5 months in the IM group (P = 0.2). Immunogenicity to hepatitis B vaccination by the SQ and IM routes is similar.
Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/inmunología , Trastornos de la Coagulación Sanguínea Heredados/virología , Recolección de Datos , Bases de Datos Factuales , Vacunas contra Hepatitis B/administración & dosificación , Vacunas contra Hepatitis B/inmunología , Niño , Preescolar , Femenino , Anticuerpos contra la Hepatitis B/inmunología , Vacunas contra Hepatitis B/efectos adversos , Humanos , Lactante , Inyecciones Intramusculares , Inyecciones Subcutáneas , Masculino , Estudios Retrospectivos , VacunaciónRESUMEN
Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology. Recombinant factor VIIa interacts with thrombin-activated platelets to produce a thrombin burst leading to accelerated fibrin clot formation localized to the site of vascular injury. It is approved in many countries for use as an intravenous hemostatic agent in patients with congenital hemophilia with inhibitors, and also for acquired hemophilia, factor VII deficiency, and Glanzmann thrombasthenia in some countries. Studies have shown it to be effective and generally well tolerated when used intravenously to treat bleeding episodes or provide hemostatic cover during surgery in patients with congenital hemophilia with inhibitors, acquired hemophilia, factor VII deficiency or Glanzmann thrombasthenia. Based on available data, its efficacy in terms of patient-assessed response may be similar to that of activated prothrombin complex concentrate (aPCC), but treatment with a single 270 microg/kg dose of recombinant factor VIIa might reduce the need for rescue therapy compared with aPCC. Recombinant factor VIIa is not immunogenic in patients with hemophilia, does not produce an anamnestic response in hemophilia patients with inhibitors, and has very low thrombogenicity. It is recommended in guidelines as the treatment of choice for bleeds in patients with hemophilia B with high-responding inhibitors and for patients with factor VII deficiency, and is also a first-line therapeutic option for high-responder hemophilia A patients with inhibitors and those with acquired hemophilia. Cost data from pharmacoeconomic analyses support its use in hemophilia patients with inhibitors. Thus, recombinant factor VIIa is a valuable treatment option for patients with these rare, but potentially serious, bleeding disorders.
Asunto(s)
Autoanticuerpos/sangre , Trastornos de la Coagulación Sanguínea Heredados/tratamiento farmacológico , Coagulación Sanguínea/efectos de los fármacos , Coagulantes/uso terapéutico , Factor VIIa/uso terapéutico , Hemofilia A/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea Heredados/sangre , Trastornos de la Coagulación Sanguínea Heredados/inmunología , Pérdida de Sangre Quirúrgica/prevención & control , Coagulantes/administración & dosificación , Coagulantes/efectos adversos , Coagulantes/economía , Coagulantes/inmunología , Análisis Costo-Beneficio , Costos de los Medicamentos , Deficiencia del Factor VII/sangre , Deficiencia del Factor VII/tratamiento farmacológico , Factor VIIa/administración & dosificación , Factor VIIa/efectos adversos , Factor VIIa/economía , Factor VIIa/inmunología , Hemofilia A/sangre , Hemofilia A/inmunología , Humanos , Proteínas Recombinantes/uso terapéutico , Trombastenia/sangre , Trombastenia/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Neonatal hemochromatosis is a rare congenital disorder of the liver associated to a poor prognosis. Liver transplantation is often required, since no effective medical treatment has been found. Despite mounting evidence of an alloimmune etiology of this condition, exchange transfusion has never been proposed as a specific treatment for neonatal hemochromatosis. Here we describe two siblings affected by neonatal hemochromatosis. The first, a female, died at 18 days of severe coagulopathy and acute renal failure, diagnosed as affected by neonatal hemochromatosis only when the second sibling was suspected as being affected by the same disease. The second child showed a rapidly worsening coagulopathy which was treated with two exchange transfusions, followed by rapid clinical and laboratory improvement, before reaching a definite diagnosis of neonatal hemochromatosis. He is healthy at present after a follow-up of 12 months. Although exchange transfusion has never been considered as treatment for neonatal hemochromatosis, this case suggests that it could be a feasible treatment option for children affected by this disease, as for other alloimmune conditions.